JORGE E CORTES to Tumor Cells, Cultured
This is a "connection" page, showing publications JORGE E CORTES has written about Tumor Cells, Cultured.
Connection Strength
0.173
-
Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873.
Score: 0.020
-
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32.
Score: 0.018
-
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74.
Score: 0.017
-
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
Score: 0.017
-
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One. 2013; 8(10):e78453.
Score: 0.017
-
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15; 73(18):5775-86.
Score: 0.016
-
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008 Jun; 22(6):1117-24.
Score: 0.011
-
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007 Sep; 117(9):2408-21.
Score: 0.011
-
Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9.
Score: 0.011
-
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404.
Score: 0.011
-
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24.
Score: 0.010
-
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br J Haematol. 2004 Mar; 124(6):727-38.
Score: 0.008
-
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9.
Score: 0.006